利用疾病活动度评分对BP进行临床可操作分层并揭示可靶向炎症内型
该队列研究纳入143例大疱性类天疱疮(BP)患者,按BPDAI荨麻疹/红斑亚评分将患者分为炎症型(I-BP)和少炎症型(PI-BP),比较临床特征、实验室指标及治疗结局,并对37例进行血清蛋白质组学分析。结果显示I-BP患者嗜酸性粒细胞计数、IL-5水平更高、住院时间更长,IL-13对I-BP内型诊断准确性最高(AUC=0.87),提示BPDAI荨麻疹/红斑亚评分可作为Th2驱动分子内型的临床替代指标。
要点
- BPDAI荨麻疹/红斑亚评分≥5可识别炎症型BP(I-BP)。
- I-BP患者嗜酸性粒细胞计数和血清IL-5水平显著升高。
- I-BP组中IL-13对内型诊断准确性最高(AUC=0.87)。
核心结论
- BPDAI荨麻疹/红斑亚评分是BP中Th2驱动分子内型的可靠临床替代指标。
- 炎症表型中鉴定出特定Th2配体-JAK/STAT信号回路,支持分层治疗策略。
研究设计与样本
- 队列研究纳入143例于2024年1月至2025年6月在一家三级中心住院的BP患者。
- 依据BPDAI荨麻疹/红斑亚评分第一四分位数将患者分为I-BP(亚评分≥5)和PI-BP(亚评分<5)。
- 对代表性亚组(n=37)进行血清蛋白质组学分析(Olink Target 96 Inflammation)。
主要发现
- 143例患者中108例(75.5%)为I-BP,35例(24.5%)为PI-BP;平均(SD)年龄73.9(11.2)岁,男性84例(58.7%)。
- 与PI-BP相比,I-BP患者更年轻、瘙痒更严重,外周血嗜酸性粒细胞计数显著升高(0.6 vs. 0.2 × 10^9 cells L-1;P=0.001),血清IL-5水平显著升高(19.8 vs. 3.9 pg mL-1;P=0.007)。
- 尽管接受更强化治疗,I-BP患者中位住院时间更长(8 vs. 7天;P=0.03)。
- 蛋白质组学分析鉴定出8个差异表达蛋白;IL-13、胸腺基质淋巴细胞生成素、制瘤素M和单核细胞趋化蛋白-4在I-BP中上调,并与荨麻疹/红斑亚评分正相关(P<0.05),但与糜烂/水疱亚评分无关。
- IL-13对I-BP内型诊断准确性最高(AUC=0.87);功能富集分析证实I-BP组中2型炎症和JAK/STAT信号通路差异激活。
关键数值与推荐
- I-BP定义为BPDAI荨麻疹/红斑亚评分≥5,PI-BP定义为亚评分<5。
- IL-13对I-BP内型的诊断AUC为0.87。
临床怎么用
- BPDAI荨麻疹/红斑亚评分可用于临床识别Th2驱动的炎症型BP患者。
- 高炎症负荷患者可能受益于靶向2型免疫治疗或JAK抑制剂,尚需前瞻性验证。
局限性
- 蛋白质组学分析仅在代表性亚组(n=37)中进行。
- 靶向治疗建议需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bullous pemphigoid (BP) exhibits significant clinical heterogeneity. The molecular drivers underlying these distinct phenotypes remain poorly understood, hindering the development of precision medicine approaches. OBJECTIVES: To correlate clinical phenotypes, defined by the Bullous Pemphigoid Disease Area Index (BPDAI), with molecular endotypes using serum proteomic profiling. METHODS: This cohort study enrolled 143 patients with BP hospitalized at a tertiary centre between January 2024 and June 2025. Patients were stratified as having inflammatory BP (I-BP; BPDAI urticaria/erythema subscore ≥ 5) and pauci-inflammatory BP (PI-BP; BPDAI urticaria/erythema subscore < 5) based on the first quartile of the subscore. Clinical features, laboratory parameters and treatment outcomes were compared. Serum proteomic profiling (Olink Target 96 Inflammation) was performed in a representative subset (n = 37). RESULTS: Of the 143 enrolled patients [mean (SD) age 73.9 (11.2) years; 84 (58.7%) men], 108 (75.5%) were classified as having I-BP and 35 (24.5%) as having PI-BP. Compared with those with PI-BP, patients with I-BP were younger, had more severe pruritus and had significantly elevated peripheral eosinophil counts (0.6 vs. 0.2 × 109 cells L-1; P = 0.001) and serum interleukin (IL)-5 levels (19.8 vs. 3.9 pg mL-1; P = 0.007). Despite receiving more intensive therapy, patients with I-BP required a longer median hospital stay (8 vs. 7 days; P = 0.03). Proteomic analysis identified eight differentially expressed proteins. IL-13, thymic stromal lymphopoietin, oncostatin M and monocyte chemoattractant protein-4 were upregulated in I-BP and showed positive correlation with the urticaria/erythema subscore (P < 0.05) but not with the erosions/blisters subscore. IL-13 demonstrated the highest diagnostic accuracy for the I-BP endotype (area under the curve = 0.87). Functional enrichment analysis confirmed differential activation of type 2 inflammation and the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling pathway in the I-BP group. CONCLUSIONS: The BPDAI urticaria/erythema subscore serves as a reliable clinical surrogate for a T helper 2 (Th2)-driven molecular endotype in BP. The identification of a specific Th2 ligand-JAK/STAT signalling circuit in the inflammatory phenotype supports a stratified treatment approach, suggesting that patients with a high inflammatory burden may benefit from targeted type 2 immunotherapies or JAK inhibitors, which warrants further prospective validation. Bullous pemphigoid (pronounced ‘bull-us pem-fih-goyd’) is a rare skin disease that causes blistering. How severe the disease is varies a lot in different people. For example, some people experience severe inflammation and itching, while others do not. We usually call the disease ‘BP’ for short. We investigated whether certain biological processes cause different symptoms. This will help doctors decide on the best treatment for patients. We divided 143 people with BP into two different groups based on how inflamed their skin was. We did this using a simple skin scoring system. We compared how patients’ skin looked and used advanced blood tests to identify causes of BP. Patients who had more inflamed-looking skin had more severe disease. They also had longer hospital stays. Their blood showed a unique molecular pattern that activates a specific inflammation pathway in the body (the JAK/STAT pathway). A simple skin score could help doctors identify people with the highly inflammatory subtype of BP. People with this subtype may benefit from early treatment with specific drugs. This would support a more personalized treatment strategy for patients.
引用
- Cao Z, Kong S, Ye J, et al. A clinically actionable stratification of bullous pemphigoid using a disease activity score reveals a targetable inflammatory endotype. Br J Dermatol. 2026. PMID: 42019951. doi:10.1093/bjd/ljag156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。